News
GPCR
50.17
+4.09%
1.97
What's Going On With Structure Therapeutics Stock On Wednesday?
Benzinga · 15h ago
BUZZ-Eli Lilly rises after US FDA approves weight-loss pill
Reuters · 17h ago
Weekly Report: what happened at GPCR last week (0323-0327)?
Weekly Report · 3d ago
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster
Seeking Alpha · 5d ago
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
NASDAQ · 03/23 14:53
Weekly Report: what happened at GPCR last week (0316-0320)?
Weekly Report · 03/23 09:09
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 03/21 14:56
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR)
TipRanks · 03/17 13:30
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity
TipRanks · 03/17 12:25
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target
Seeking Alpha · 03/17 11:45
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 03/17 11:30
STRUCTURE THERAPEUTICS INC <GPCR.O>: BMO RAISES TARGET PRICE TO $145 FROM $130
Reuters · 03/17 10:49
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Reuters · 03/17 07:31
Structure Therapeutics rises on mid-stage data for oral GLP-1
Seeking Alpha · 03/16 16:27
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100
Benzinga · 03/16 16:13
Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/16 16:12
Structure Therapeutics Price Target Cut to $100.00/Share From $114.00 by HC Wainwright & Co.
Dow Jones · 03/16 16:12
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 03/16 16:00
Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright
TipRanks · 03/16 15:55
Buy Rating on Structure Therapeutics: Aleniglipron’s Strengthening Clinical Profile and Undervalued Global Obesity Opportunity
TipRanks · 03/16 15:55
More
Webull provides a variety of real-time GPCR stock news. You can receive the latest news about Structure Therapeutics Inc ADR through multiple platforms. This information may help you make smarter investment decisions.
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.